iRhythm Technologies, Inc.: management transactions · United States · SEC (Form 4)

About iRhythm Technologies, Inc.

iRhythm Technologies, Inc. (NASDAQ: IRTC) is a U.S.-based digital health company focused on ambulatory cardiac arrhythmia diagnosis. Headquartered in San Francisco, California, United States, the company was incorporated in September 2006 and began commercializing its solutions in the United States in 2009 following FDA clearance. For international investors, iRhythm sits at the intersection of medtech, software, wearable sensors, and data analytics, with a business model centered on recurring clinical monitoring services rather than a one-off device sale. The company’s core platform is Zio, a prescription-based ambulatory ECG monitoring system designed to capture cardiac activity continuously for up to 14 days. The offer includes the Zio patch and the ZEUS software platform, which uses cloud-based analytics and AI-enabled interpretation to convert raw ECG data into clinically actionable reports. iRhythm also markets Zio AT, a mobile cardiac telemetry solution. The strategic strength of the franchise lies in its integrated workflow: patient-friendly wearables, data capture, algorithmic review, and clinician-ready outputs are delivered in one connected service model. From a competitive standpoint, iRhythm is a recognized specialist in ambulatory cardiac monitoring, a niche where diagnostic accuracy, patient adherence, and the ability to detect intermittent arrhythmias are crucial. The company differentiates itself through its deep data set, AI capabilities, and a strong emphasis on clinical evidence and operational ease of use. iRhythm has stated that it has served more than 8 million patients and accumulated more than 1.5 billion hours of heartbeat data, which supports the improvement of its algorithms and its long-term product moat. Geographically, iRhythm remains primarily U.S.-focused, with the majority of revenue historically generated in the domestic market. That said, the company is building an international footprint, including a United Kingdom presence and the 2025 launch of Zio in Japan through a local distribution partner. This supports a broader expansion story, although reimbursement, regulatory approvals, and physician adoption remain central execution variables. Recent developments have reinforced the investment case. In 2025 and 2026, the company highlighted new clinical and real-world data supporting the benefits of the Zio portfolio for arrhythmia detection across multiple patient populations. It also received FDA clearance for design modifications to Zio AT in 2024 and raised its 2026 revenue guidance in early 2026. Overall, iRhythm is a growth-oriented Health & Pharma name listed on the NASDAQ in the United States, combining medical innovation, evidence generation, and selective geographic expansion.